Rezultati pretraživanja
  1. prije 4 sata

    Date time: 02/05/2020 10:18 PM EST Stock: Market Price: 102.47 Buy calls, forex model, sell at: 108.85

  2. Neurocrine Biosciences Issues Earnings Results, Misses Estimates By $0.40 EPS

  3. prije 17 sati

    reported a press of the firm’s earnings yesterday. Higher accruals in a firm’s reported earnings, poorer future earnings. see

  4. prije 18 sati

    CS We’re not negative on non-Ingrezza pipeline,data remain relatively immature&potential opportunities for later-stage assets are on smaller side. Opicapone is likely to be approved by FDA (PDUFA of 4/26/20),believe opportunity relatively small with $400-500M in peak sales

  5. prije 18 sati

    H.C. Wainwright raises PT for to $125 , reiterated at a Buy rating

  6. prije 19 sati
  7. 5. velj

    Earnings Intelligence Analysis of recent earnings identified Neurocrine Biosciences, Inc (NASDAQ: NBIX ) business focus on (guidance,ingrezza), (ingrezza,prescriptions), (ingrezza,product)

  8. 4. velj

    $238M Q4 Ingrezza sales, $753M FY19 Expense guidance for 2020 below Nothing rly unexpected

  9. 4. velj

    Neurocrine Biosciences EPS beats by $0.30, beats on revenue

  10. GOOD sentiment for earnings this afternoon:

  11. 4. velj
  12. 3. velj

    Big week ahead 2/3 2/4 2/6 Tecfidera IPR 2/6 SUNFISH 2/7 EAHAD 2/8 wet-AMD 2/8 DME Earnings 2/4 2/5 2/6 2/7

  13. 1. velj

    Introducing monthly update series of main portfolio Focus on small/mid cap biotech/SaaS/life sciences. YTD: Portfolio +4.12% SPY -0.16% About 5% in cash. From biggest to smallest position:

  14. 31. sij
  15. 30. sij

    Healthcare Opportunities: "biotech ETF fighting at very round 90 number. records second worst weekly return last week in over a year. well in bear market mode off 23% from most recent 52 week highs."

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.